NouvNeu Biotechnology

NouvNeu Biotechnology is a regenerative medicine company dedicated to developing transformative therapies for neurodegenerative and ophthalmic conditions. Founded on the pioneering research of Dr. Xiang-Dong Fu, the company utilizes an in vivo transdifferentiation platform to convert non-neuronal cells into functional neurons. Their proprietary approach employs adeno-associated virus (AAV) vectors to deliver shRNA targeting the RNA-binding protein PTBP1, facilitating the replacement of lost neurons in situ. The company's lead pipeline program is focused on treating Parkinson's disease by regenerating dopaminergic neurons in the substantia nigra. NouvNeu has secured significant backing from prominent venture capital firms to advance its pipeline toward clinical trials.